Getting the Right Evidence After Drug Approval

by Rick A. Vreman, Rick A. Vreman, Hubert G. M. Leufkens, Aaron S. Kesselheim
Published 2020-09-01

Application of Managed Entry Agreements for Innovative Therapies in Different Settings and Combinations: A Feasibility Analysis

by Rick A. Vreman, Thomas F. Broekhoff, Hubert G.M. Leufkens, Aukje K. Mantel-Teeuwisse, Wim G. Goettsch
Published 2020-11-01

Bridging the gap: Can International Consortium of Health Outcomes Measurement standard sets align outcomes accepted for regulatory and health technology assessment decision‐making...

by Rachel R. J. Kalf, Rick A. Vreman, Diana M.J. Delnoij, Marcel L. Bouvy, Wim G. Goettsch
Published 2021-04-01

Increasing the information provided by probabilistic sensitivity analysis: The relative density plot

by Joost W. Geenen, Rick A. Vreman, Cornelis Boersma, Olaf H. Klungel, Anke M. Hövels, Renske M. T. Ten Ham
Published 2020-11-01

Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies

by Lourens T. Bloem, Rick A. Vreman, Niels W. L. Peeters, Jarno Hoekman, Menno E. van derElst, Hubert G. M. Leufkens, Olaf H. Klungel, Wim G. Goettsch, Aukje K. Mantel‐Teeuwisse
Published 2021-07-01